CCR2 and fatty liver disease: Similarly, the inhibition of CCR2 also attenuates diet-induced insulin resistance and hepatic steatosis in obese mice (137, 138), suggesting that MCP1/CCR2 could be a potential therapeutic target in obesity-associated metabolic complications.